menu
    • menu

    Company profile for NeoTX Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a pow...
    NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful, yet safe, native antibacterial immune reaction.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NeoTX TherapeuticsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    2 Pekeris Street Rehovot
    Telephone
    Telephone
    +1 609 718 2305
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://neotx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NeoTX successfully completes 1st stage of PIIa trial of NAP+docetaxel in NSCLC
    NeoTX successfully completes 1st stage of PIIa trial of NAP+docetaxel in NSCLC

    01 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neotx-announces-successful-first-stage-completion-of-its-phase-2a-clinical-trial-of-naptumomab-estafenatox-nap-in-combination-with-docetaxel-in-advanced-non-small-cell-lung-cancer-nsclc-301558939.html

    PRNEWSWIRE
    01 Jun 2022
    Share Share
    NeoTX to Present at the Society for Immunotherapy Cancer's 36th Annual Meeting
    NeoTX to Present at the Society for Immunotherapy Cancer's 36th Annual Meeting

    09 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neotx-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancers-36th-annual-meeting-301419547.html

    PRNEWSWIRE
    09 Nov 2021
    Share Share
    NeoTX Announces First Patient Enrolled In Phase 2a Clinical Trial Of (NAP)
    NeoTX Announces First Patient Enrolled In Phase 2a Clinical Trial Of (NAP)

    20 Oct 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neotx-announces-first-patient-enrolled-in-phase-2a-clinical-trial-of-naptumomab-estafenatox-nap-its-lead-tumor-targeted-superantigen-tts-candidate-in-combination-with-docetaxel-in-patients-with-advanced-non-small-cell-lung-c-301404001.html

    PRNEWSWIRE
    20 Oct 2021
    Share Share
    NeoTX Hosting KOL Webinar on Overcoming Check Point Inhibitor Resistance
    NeoTX Hosting KOL Webinar on Overcoming Check Point Inhibitor Resistance

    07 Jul 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/07/07/2259408/0/en/NeoTX-Hosting-Key-Opinion-Leader-Webinar-on-Overcoming-Check-Point-Inhibitor-Resistance.html

    GLOBENEWSWIRE
    07 Jul 2021
    Share Share
    US FDA clears NeoTX’s IND application for ph 2 trial of naptumomab estafenatox
    US FDA clears NeoTX’s IND application for ph 2 trial of naptumomab estafenatox

    20 Apr 2021

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/us-fda-clears-neotxs-ind-application-for-ph-2-trial-of-naptumomab-estafenatox-1622781642.pdf

    PRESS RELEASE
    20 Apr 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search